1.
Vopr Onkol
; 61(4): 667-70, 2015.
Article
in Russian
| MEDLINE
| ID: mdl-26571842
ABSTRACT
Drug therapy for symptomatic multiple myeloma is comparable for both sexes in its effectiveness and safety. A 3-year event-free survival is comparable in men and women; overall survival in men is lower than in women.